2022年癌症统计
美国癌症协会每年估算美国新发癌症病例和死亡人数,并汇总基于人群的癌症发生与结局数据。2022年预计美国新发癌症病例1,918,030例、癌症死亡609,360例,其中肺癌是主要死因,约每天350例死亡。乳腺癌和前列腺癌进展停滞,肺癌进展加强,与筛查和/或治疗实践变化相吻合。
要点
- 2022年美国预计新发癌症1,918,030例,癌症死亡609,360例。
- 肺癌是癌症死亡首要原因,预计每天约350例死亡。
- 乳腺癌发病率2014-2018年每年缓慢增加0.5%,前列腺癌稳定但晚期疾病2011年以来每年增加4%-6%。
核心结论
- 乳腺癌和前列腺癌的进展停滞,而肺癌的进展加强,与癌症筛查和/或治疗相关的医疗实践变化相吻合;更有针对性的癌症控制干预和对改进早期检测与治疗的投资将有助于降低癌症死亡率。
研究设计与样本
- 美国癌症协会每年估算美国新发癌症病例和死亡人数,并汇编基于人群的癌症发生与结局最新数据。
- 发病率数据(至2018年)来自监测、流行病学和最终结果项目、国家癌症登记项目及北美中央癌症登记协会;死亡率数据(至2019年)来自国家卫生统计中心。
主要发现
- 2022年美国预计发生1,918,030例新发癌症病例和609,360例癌症死亡,其中肺癌是癌症死亡首要原因,预计每天约350例死亡。
- 2014年至2018年女性乳腺癌发病率继续缓慢增加(每年增加0.5%),前列腺癌发病率保持稳定,但晚期疾病自2011年以来每年增加4%至6%。
- 过去十年,远处转移期诊断的前列腺癌比例从3.9%增加至8.2%。
- 肺癌晚期疾病发病率继续急剧下降,而局限期发病率突然每年增加4.5%,促使局限期诊断比例从2004年的17%增加至2018年的28%,3年相对生存率从21%增加至31%。
- 死亡率模式反映发病率趋势:肺癌死亡率下降加速,乳腺癌死亡率下降放缓,前列腺癌死亡率趋于稳定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate cancer, despite a 4% to 6% annual increase for advanced disease since 2011. Consequently, the proportion of prostate cancer diagnosed at a distant stage increased from 3.9% to 8.2% over the past decade. In contrast, lung cancer incidence continued to decline steeply for advanced disease while rates for localized-stage increased suddenly by 4.5% annually, contributing to gains both in the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and 3-year relative survival (from 21% to 31%). Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and stabilizing for prostate cancer. In summary, progress has stagnated for breast and prostate cancers but strengthened for lung cancer, coinciding with changes in medical practice related to cancer screening and/or treatment. More targeted cancer control interventions and investment in improved early detection and treatment would facilitate reductions in cancer mortality.
引用
- Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022. PMID: 35020204. doi:10.3322/caac.21708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。